Predictive Biomarkers Market Report 2025

This predictive biomarkers market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The predictive biomarkers market size has grown steadily in recent years. It will grow from $20.05 billion in 2024 to $20.96 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to increasing research and development investments, expansion of healthcare infrastructure, collaborations between academic institutions and industry, growing incidence of cancer and genetic disorders, and increased use of biomarkers in drug development.

The predictive biomarkers market size is expected to see steady growth in the next few years. It will grow to $24.67 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to increasing adoption of precision medicine, growing focus on preventive healthcare, rising healthcare expenditure, increased investment in biomarker-based diagnostics, expansion of biobanks and tissue repositories, and a rise in global health awareness. Major trends in the forecast period include integration of artificial intelligence in biomarker analysis, development of non-invasive biomarker testing, advancements in biomarker-based digital health tools, advancement in single-cell sequencing technologies, development of real-time biosensing and monitoring systems, and advancement in bioinformatics tools for data integration.

The increasing incidence of cancer is expected to drive the growth of the predictive biomarkers market. Cancer is characterized by uncontrolled cell growth that can invade and spread to other parts of the body. This rise in cancer cases is largely due to aging populations, lifestyle changes, and greater exposure to risk factors such as tobacco use, poor diets, and environmental pollutants. Predictive biomarkers help identify patients who are likely to benefit from specific treatments, enabling more personalized and effective therapies. For example, a report by the International Agency for Research on Cancer (IARC), a France-based agency of the World Health Organization (WHO) specializing in cancer research, indicated in April 2024 that there were nearly 20 million new cancer cases and about 10 million cancer-related deaths in 2022. Projections suggest that the number of new cancer cases will increase to 35 million annually by 2050, representing a 77% rise from 2022 levels. Consequently, the growing number of cancer cases is expected to boost the predictive biomarkers market.

Major companies in the predictive biomarkers market are increasingly leveraging technological advancements, such as AI-driven biomarker discovery, to accelerate biomarker development. This approach helps them gain a competitive edge by delivering more personalized and effective therapies more quickly. AI-driven biomarker discovery facilitates the analysis of large, complex datasets, uncovering predictive biomarkers that traditional methods might miss. For example, in July 2024, Scipher Medicine, Inc., a US-based precision immunology company, introduced PRoBeNet (Predictive Response Biomarkers using Network Medicine). This platform aims to speed up the development of predictive response biomarkers for complex diseases by using AI and network biology. PRoBeNet identifies biomarkers related to therapy response by integrating therapy-targeted proteins with disease-specific molecular signatures. It has been validated for autoimmune conditions such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease, and is applicable to other complex diseases and drug development stages.

In January 2023, Thermo Fisher Scientific Inc., a US-based biotechnology research company, acquired The Binding Site Group for £2.3 billion. This acquisition aims to strengthen Thermo Fisher's specialty diagnostics segment by incorporating The Binding Site's advanced diagnostic technologies, thereby enhancing oncology testing and patient care for multiple myeloma. The Binding Site Group, a UK-based provider of diagnostic solutions, offers various predictive biomarkers, especially in the fields of hematology and immunology.

Major companies operating in the predictive biomarkers market are Johnson & Johnson Services Inc, F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthcare GmbH, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Bio-Rad Laboratories Inc, QIAGEN GmbH, Almac Group Limited, ArcherDX Inc, Luminex Corporation, Guardant Health Inc, Meso Scale Diagnostics LLC, Myriad Genetics Inc, NanoString Technologies Inc, Fujirebio Inc, Asuragen Inc, Biognosys AG, Epigenomics AG, OncoCyte Corporation, Biomarker Technologies Inc.

North America was the largest region in the predictive biomarkers market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the predictive biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Predictive biomarkers are biological indicators that help forecast an individual’s likelihood of developing a disease or their response to a specific treatment. These markers, which can be genetic, proteomic, or molecular, provide valuable insights into disease susceptibility or treatment efficacy. They enable personalized treatment approaches, enhancing the effectiveness of interventions and potentially reducing adverse effects by identifying patients who are most likely to benefit from specific therapies.

The main indication types for predictive biomarkers include cancer, metabolic diseases, cardiovascular disorders, immunological disorders, and others. Predictive biomarkers for cancer, for example, can reveal a person’s risk of developing cancer or predict their response to certain treatments. These biomarkers may include genetic mutations, protein levels, or other biological factors indicative of cancer presence or progression. Applications of predictive biomarkers encompass screening, analysis, diagnosis, prediction, and monitoring. End users of these biomarkers include diagnostic centers, contract research organizations, academic research institutes, pharmaceutical and biotech companies, and other relevant entities.

The predictive biomarkers market research report is one of a series of new reports that provides predictive biomarkers market statistics, including predictive biomarkers industry global market size, regional shares, competitors with an predictive biomarkers market share, detailed predictive biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the predictive biomarkers industry. This predictive biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The predictive biomarkers market consists of revenues earned by entities by providing services such as biomarker discovery, validation, and testing, as well as genetic screening, data analysis, and personalized medicine solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The predictive biomarkers market also includes sales of genetic testing kits, molecular diagnostic assays, genomic sequencing tools, and bioinformatics software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.